

1988 INDEX

A

- Abscess: pyogenic, after interferon in hepatitis B, *Mar.*, 134
- Acetazolamide in congestive heart failure, *Aug.*, 510
- dosage and pharmacokinetic characteristics of, *Aug.*, 512
- Achalasia, *June*, 335-347
- barium esophagram in, *June*, 342
- clinical manifestations of, *June*, 340
- complications of, *June*, 342-343
- cricopharyngeal, *June*, 362
- DES association, *June*, 349
- diagnosis of, *June*, 341-342
- differential, *June*, 343-344
- etiology of, *June*, 338-340
- myotomy vs. forceful dilatation in, *June*, 346
- pathophysiology of, *June*, 338-340
- radiograph in, chest, *June*, 341
- therapy of, *June*, 344-347
- Acid
- base disturbances in ICU patients, *May*, 273-276
- perfusion test in gastroesophageal reflux, *June*, 369
- reflux test, standard, in gastroesophageal reflux, *June*, 370
- Acidosis
- in hypoadosteronism, hyporeninemic, *Oct.*, 654-655
- metabolic, in ICU, *May*, 276
- ACTH
- assay, plasma, *Oct.*, 622
- dependent hypercortisolism, pituitary (*see* Hypercortisolism, pituitary ACTH-dependent)
- releasing hormone test in Cushing's syndrome, *Oct.*, 623
- secretion, ectopic
- etiology of, *Oct.*, 615
- treatment of, *Oct.*, 627
- test, rapid, in Addison's disease, *Oct.*, 635-636
- Acyclovir: in hepatitis B, *Mar.*, 134-135
- Addison's disease, *Oct.*, 627-638
- (*See also* Adrenal, insufficiency)
- ACTH test in, rapid, *Oct.*, 635-636
- adrenal hemorrhage causing, *Oct.*, 630-631
- adrenalitis causing, autoimmune, *Oct.*, 628
- associations of, *Oct.*, 634
- clinical features of, *Oct.*, 632-634
- diagnosis of
- etiological, *Oct.*, 637
- laboratory, *Oct.*, 635-637
- in elderly, *July*, 420
- etiology of, *Oct.*, 628-632
- rare, *Oct.*, 630-632
- infections causing, *Oct.*, 629-630
- laboratory confirmation of, *Oct.*, 636-637
- laboratory tests in, nonspecific, *Oct.*, 635
- metastatic, *Oct.*, 630
- screening for, *Oct.*, 635-637
- treatment of, *Oct.*, 638
- Adenine arabinoside and adenine arabinoside monophosphate: in hepatitis B virus infection, *Mar.*, 135-136
- Adenocarcinoma: endometrial, and estrogen therapy, in elderly, *July*, 438
- Adenoma
- aldosterone-producing
- distinction between idiopathic hyperplasia and, *Oct.*, 645-646
- hyperaldosteronism due to, *Oct.*, 639
- parathyroid, preoperative localization of, *Dec.*, 767-770
- Adenomatosis: cystic parathyroid, *Dec.*, 760
- Adrenal
- androgens, in elderly, *July*, 422-423

Adrenal (*cont.*)

- cortex
 - diseases of, *Oct.*, 613-674
 - in elderly, *July*, 419-423
 - nodular dysplasia, primary, *Oct.* 615
- hemorrhage causing Addison's disease, *Oct.*, 630-631
- hyperplasia
 - bilateral, causing hyperaldosteronism, *Oct.*, 639-640
 - idiopathic, distinction between aldosterone-producing adenoma and, *Oct.*, 645-646
 - macronodular, bilateral, treatment of, *Oct.*, 627
- hypothalamic-pituitary axis, in elderly, *July*, 420
- insufficiency
 - (*See also* Addison's disease)
 - drug-induced, *Oct.*, 631-632
 - hypercalcemia due to, *Dec.*, 776-777
 - medulla, in elderly, *July*, 423-424
 - steroidogenesis, *Oct.*, 658
 - tumors causing Cushing's syndrome (*see* Cushing's syndrome, adrenal tumors causing)
 - vein catheterization, bilateral, in primary hyperaldosteronism, *Oct.*, 648-649
- Adrenalectomy: bilateral, in Cushing's syndrome, *Oct.*, 626
- Adrenalitis: autoimmune, causing Addison's disease, *Oct.*, 628
- Adrenergic
 - agonists, beta-, in congestive heart failure, *Aug.*, 517-518
 - antagonists, beta-, in primary hyperparathyroidism, *Dec.*, 770
- blockers
 - alpha, in chronic hypoxic cor pulmonale, *Sept.*, 579
 - beta (*see* Beta blockers)
- receptor: alpha-, in elderly, *July*, 424
- responsiveness, in elderly, *July*, 423-424

- Adrenocorticotrophic hormone (*see* ACTH)
- Adrenogenital syndromes, *Oct.*, 657-665
 - pathophysiology of, *Oct.*, 657-659
 - treatment of, *Oct.*, 664-665
- Age-related alterations
 - in bone and calcium homeostasis, *July*, 427-429
 - in PTH physiology, *July*, 424-425
- Aged (*see* Elderly)
- Agitation: and hypomagnesemia, *Apr.*, 190
- Airway
 - disease, small, definition of, *Sept.* 552-554
 - limitation, definition of, *Sept.*, 550
 - obstruction, definition of, *Sept.* 550-551
- Alcohol
 - esophageal motility disorders due to, *June*, 367
 - heart failure and, congestive, *Aug.*, 507-508
- Alcoholism: chronic, hypomagnesemia in, *Apr.*, 196
- Aldosterone
 - producing adenoma (*see* Adenoma, aldosterone-producing)
 - renin-angiotensin-aldosterone system (*see* Renin, -angiotensin-aldosterone system)
 - response to standing posture between 8 AM and noon, in primary hyperaldosteronism, *Oct.*, 646-647
- Alkali: milk-alkali syndrome, *Dec.*, 780
- Alkalosis: metabolic, in ICU, *May*, 273-276
- Almitrine bismesylate: in COPD, *Sept.*, 585-586
- Alpha-adrenergic blockers: in chronic hypoxic cor pulmonale, *Sept.*, 579
- Alpha-adrenergic receptor: in elderly, *July*, 424
- Alpha-methyldopa-induced chronic hepatitis, *Mar.*, 150

- Alzheimer's disease: hormonal alterations in, *July*, 447-448
- Amantadine: preventing influenza in COPD, *Sept.*, 577
- Amenorrhea: in Addison's disease, *Oct.*, 634
- Amiloride: in congestive heart failure, *Aug.*, 512
- Aminoglutethimide: in Cushing's syndrome, *Oct.*, 627
- Aminoglycosides
hypomagnesemia due to, *Apr.*, 195
interactions with other drugs, in ICU, *May*, 283
nephrotoxicity, in ICU, *May*, 268
prevention of, *May*, 270
- Amniocentesis: in 21-hydroxylase deficiency, *Oct.*, 663
- Amoxicillin: in COPD, *Sept.*, 574
- Amphotericin B: causing hypomagnesemia, *Apr.*, 195
- Ampicillin: in COPD, *Sept.*, 574
- Amrinone: in congestive heart failure, *Aug.*, 517
- Amyl nitrate test: in achalasia, *June*, 343
- Amyloid polyneuropathy: familial, esophageal motility disorders in, *June*, 366
- Amyloidosis: systemic, esophagus in, *June*, 366
- Amyotrophy: diabetic, in elderly, *July*, 444
- Androgen(s)
adrenal, in elderly, *July*, 422-423
status in elderly male, *July*, 433
therapy in elderly male, *July*, 435-436
- Anemia: and primary hyperparathyroidism, *Dec.*, 759
- Angiography
findings in stable coronary heart disease, exercise test predicting, *Nov.*, 700-706
examples of, *Nov.*, 703-706
nuclear, in congestive heart failure, *Aug.*, 500
- Angiotensin (see Renin, -angiotensin-aldosterone system)
- Anorexia: of aging, *July*, 448-449
- Antacids: interactions with other drugs in ICU, *May*, 283
- Antiarrhythmics: in congestive heart failure, *Aug.*, 524-525
- Antibiotics: causing hypomagnesemia, *Apr.*, 195
- Anticholinesterases: in hypermagnesemia, *Apr.*, 207
- Anticoagulants: in congestive heart failure, *Aug.*, 525
- Anticoagulation: and Addison's disease, *Oct.*, 631
- Antidepressants: tricyclic, in psychiatric ICU syndromes, *May*, 286
- Antiestrogens: causing hypercalcemia, *Dec.*, 779-780
- Antimicrobials: in acute infective exacerbations of COPD, *Sept.*, 573-575
- Antiviral therapy in hepatitis B, *Mar.*, 125-127
D, *Mar.*, 141-142
non-A, non-B, *Mar.*, 143
- Anxiety
hypomagnesemia and, *Apr.*, 190
in ICU patients, therapy of, *May*, 285
- Appointment scheduling: office computer for, *Jan.*, 39, 40
- Arrhythmias
digitalis-induced, frequency of, *Aug.*, 515
hypomagnesemia and, *Apr.*, 190
in ICU, *May*, 250-258
magnesium therapy in, *Apr.*, 190-191
ventricular
exercise test-induced, *Nov.*, 719-720
during Swan-Ganz catheter passage in ICU, *May*, 262
- Arteriography: for preoperative localization of parathyroid adenomas, *Dec.*, 770
- Artery
coronary (see Coronary artery)
pulmonary (see Pulmonary artery)

Arthritis: rheumatoid, esophagus in, *June*, 359

Aspiration biopsy: fine-needle, in non-small cell lung cancer, *Feb.*, 76

Asthma
bronchial, peak expiratory flow in, *Sept.*, 558

cardiac, *Aug.*, 494

chronic, *Sept.*, 554

definition of, *Sept.*, 551-552

Asthmatic bronchitis (*see* Bronchitis, chronic, asthmatic)

Atherosclerosis: and hypomagnesemia, *Apr.*, 201

Atrial
fibrillation (*see* Intensive care unit patients, atrial fibrillation in)
flutter (*see* Intensive care unit patients, atrial flutter in)
natriuretic factor, in elderly, *July*, 441
tachycardia (*see* Intensive care unit patients, tachycardia in, atrial)

Atrioventricular nodal reentrant tachycardia (*see* Intensive care unit patients, tachycardia in, atrioventricular nodal reentrant)

Augmentin: in COPD, *Sept.*, 574

Autoimmune
adrenalitis causing Addison's disease, *Oct.*, 628

hepatitis (*see* Hepatitis, autoimmune chronic active)

Automation of medical office (*see* Computer office system)

Azathioprine in autoimmune chronic active hepatitis, *Mar.*, 146

toxicity of, *Mar.*, 147-148

Aztreonam: in COPD, *Sept.*, 574

B

Balance studies: magnesium, *Apr.*, 185

Barbiturates: interactions with other drugs in ICU, *May*, 283

Barium esophagram (*see* Esophagram, barium)

Barotrauma: pulmonary, in ICU, *May*, 240

BCG: in non-small cell lung cancer, *Feb.*, 97

Benzodiazepines: in psychiatric ICU syndrome, *May*, 285, 286

Bernstein test: in gastroesophageal reflux, *June*, 369

Beta-adrenergic agonists: in congestive heart failure, *Aug.*, 517-518

Beta-adrenergic antagonists: in primary hyperparathyroidism, *Dec.*, 770

Beta blockers
in heart failure, congestive, *Aug.*, 518-519
interactions with other drugs in ICU, *May*, 283

Beta₂-agonists
in COPD, *Sept.*, 569-570
ipratropium with, *Sept.*, 570-571
ipratropium and theophylline with, *Sept.*, 571
in cor pulmonale, chronic hypoxic, *Sept.*, 579

Bethanechol: in gastroesophageal reflux, *June*, 371

Bile duct injury: in chronic hepatitis, *Mar.*, 120

Biologic response modifiers: in non-small cell lung cancer, *Feb.*, 96-98

Biopsy
endomyocardial, in congestive heart failure, *Aug.*, 500, 501
esophageal, in achalasia, *June*, 343
fine-needle aspiration, in non-small cell lung cancer, *Feb.*, 76
supraclavicular, in non-small cell lung cancer, *Feb.*, 78

Bisphosphonates
in hypercalcemia, *Dec.*, 788-790

- in hyperparathyroidism, primary, *Dec.*, 771
- Bleeding (see Hemorrhage)
- Block: transient right bundle branch, during Swan-Ganz catheter passage in ICU, *May*, 262
- Blood cells
- mononuclear, magnesium in, *Apr.*, 181-183
 - red, magnesium in, *Apr.*, 174
 - red, magnesium in, assessment of, *Apr.*, 184
- transfusion, perioperative, in non-small cell lung cancer, *Feb.*, 81
- volume regulation in congestive heart failure, *Aug.*, 488-493
- Blue bloaters, *Sept.*, 560, 562
- cor pulmonale in, *Sept.*, 565
- Body fluids: magnesium distribution in, *Apr.*, 173-174
- Bone
- disease, radiographic, in primary hyperparathyroidism, *Dec.*, 757
 - effects of hypermagnesemia, *Apr.*, 208
 - histological appearance in primary hyperparathyroidism, *Dec.*, 758
 - histomorphometry in primary hyperparathyroidism, *Dec.*, 765
 - homeostasis, age-related alterations in, *July*, 427-429
 - resorption inhibiting agents in hypercalcemia, *Dec.*, 787-791
- Boron: in osteoporosis, in female, *July*, 439
- Bougienage: in nutcracker esophagus, *June*, 353
- Breathing: sleep-disordered, in COPD, *Sept.*, 583-587
- Bretylum: in tachyarrhythmias in ICU, *May*, 249
- Bromocriptine: in Cushing's syndrome, *Oct.*, 626
- Bronchial asthma: peak expiratory flow in, *Sept.*, 558
- Bronchiectasis: differentiated from COPD, *Sept.*, 563-564
- Bronchitis, chronic, *Sept.*, 554
- asthmatic
- definition of, *Sept.*, 554
 - differentiated from COPD, *Sept.*, 565-566
 - definition of, *Sept.*, 550
- Bronchodilators: in COPD, *Sept.*, 568-573
- Bronchogenic carcinoma (see Carcinoma, bronchogenic)
- Bulbar
- palsy, chronic progressive, esophagus in, *June*, 364
 - poliomyelitis, esophagus in, *June*, 364
- Bumetanide: in congestive heart failure, *Aug.*, 510
- Bundle branch block: transient right, during Swan-Ganz catheter passage in ICU, *May*, 262
- Bypass: coronary, prognostic value of exercise test in predicting improved survival after, *Nov.*, 723-725, 726

C

- Cachexia: diabetic neuropathic, in elderly, *July*, 444
- Calcitonin
- calcium regulation by, serum, *Dec.*, 753
 - salmon, in osteopenia, in elderly, *July*, 431
 - therapy in hypercalcemia, *Dec.*, 790
- Calcium
- channel blockers
 - in achalasia, *June*, 347
 - in esophageal spasm, diffuse, *June*, 351
 - interactions with other drugs in ICU, *May*, 283
 - in nutcracker esophagus, *June*, 353
 - circulating, measurement of, *Dec.*, 749-750

Calcium (*cont.*)

gastrointestinal absorption of, excessive, causing hypercalcemia, therapy of, *Dec.*, 791-792

homeostasis

age-related alterations in, *July*, 427-429

general principles of, *Dec.*, 749-753

in hypermagnesemia, *Apr.*, 207

release and reaccumulation in heart, *Aug.*, 481

serum

calcitonin regulating, *Dec.*, 753

1,25-dihydroxyvitamin D regulating, *Dec.*, 751-753

mean, before and after parathyroidectomy, *Dec.*, 768

parathyroid hormone regulating, *Dec.*, 750-751

regulation of, *Dec.*, 750-753

Cancer

hypomagnesemia and, *Apr.*, 204

lung, non-small cell, *Feb.*, 61-108

BCG in, *Feb.*, 97

biologic response modifiers in, *Feb.*, 96-98

biopsy in, fine-needle aspiration, *Feb.*, 76

biopsy in, supraclavicular, *Feb.*, 78

carcinogens causing, *Feb.*, 64

chemotherapy of (see Chemotherapy of non-small cell lung cancer)

classification of, *Feb.*, 64-67

clinical features of, *Feb.*, 67-69

diagnosis of, *Feb.*, 71-79

epidemiology of, *Feb.*, 61-64

etiology of, *Feb.*, 61-64

inoperable, prognosis, *Feb.*, 80-81

mediastinoscopy in, *Feb.*, 77-78

metastases from, occult extra-thoracic, CT detecting, *Feb.*, 78-79

MRI in, *Feb.*, 77

natural history of, *Feb.*, 61-82

operability of, *Feb.*, 83-84

prevention of, *Feb.*, 61-64

prognosis, *Feb.*, 79-82

radionuclide scans in, *Feb.*, 78

radiotherapy of (see Radiotherapy of non-small cell lung cancer)

resectability of, *Feb.*, 83

screening for, *Feb.*, 69-71

smoking and, *Feb.*, 61-62

smoking and, passive, *Feb.*, 62-64

stage I, treatment, *Feb.*, 98-99

stage II, treatment, *Feb.*, 99

stage IIIA, treatment, *Feb.*, 99

stage IIIB, treatment, *Feb.*, 99

stage IV, treatment, *Feb.*, 99-100

staging, *Feb.*, 71-79

staging, new international system, *Feb.*, 71-74

staging, recommended workup, *Feb.*, 75

staging, tumor markers in, *Feb.*, 79

surgery for, *Feb.*, 82-84

surgery for, morbidity and mortality of, *Feb.*, 84

survival, *Feb.*, 75

tests in clinical evaluation of, *Feb.*, 74-79

tobacco and, *Feb.*, 61-62

tomography in, standard and computed, *Feb.*, 77

transfusion in, perioperative, *Feb.*, 81

treatment failure and death, *Feb.*, 80

treatment modalities, integration of, *Feb.*, 98-100

treatment, with single modalities, *Feb.*, 82-98

lung, as second primary, *Feb.*, 82

thyroid, in elderly, *July*, 418

Captopril

in cor pulmonale, chronic hypoxic, *Sept.*, 579

in heart failure, congestive, *Aug.*, 520-521

- Carcinogens: causing lung cancer, *Feb.*, 64
- Carcinoma
 adenocarcinoma, endometrial, and estrogen therapy, in elderly, *July*, 438
 bronchogenic
 origin of signs and symptoms at time of clinical presentation, *Feb.*, 69
 systemic effects of, *Feb.*, 68
 esophagus, squamous cell, and achalasia, *June*, 342-343
 parathyroid, in primary hyperparathyroidism, *Dec.*, 760
- Cardiac (*see* Heart)
- Cardiomyopathy: causing left ventricular failure, survival curves in, *Aug.*, 478
- Cardiovascular manifestations: of hypercalcemia, *Dec.*, 785
- Cardioversion in ICU
 for atrial fibrillation, *May*, 251
 for atrial flutter, *May*, 252
 for tachycardia
 atrioventricular nodal reentrant, *May*, 255
 ventricular, *May*, 258
- Catecholamines: in elderly, *July*, 423-424
- Catheter, Swan-Ganz (*see* Intensive care unit patients, hemodynamic monitoring complications in)
- Catheterization
 of adrenal veins, bilateral, in primary hyperaldosteronism, *Oct.*, 648-649
 venous, selective, of parathyroid adenomas, *Dec.*, 770
- Cell (*see* Blood, cells)
- Cellular basis: of cardiac contraction, *Aug.*, 477-484
- Central nervous system (*see* Nervous system, central)
- Cerebrovascular accident: esophageal motility disorders in, *June*, 364
- Chagas' disease: esophagus in, *June*, 360
- Chemotherapy of non-small cell lung cancer, *Feb.*, 89-96
 adjuvant
 postoperative, *Feb.*, 95-96
 preoperative, *Feb.*, 96
 balancing risk and benefit, *Feb.*, 95
 combination, *Feb.*, 92-95
 quality of life with, *Feb.*, 95
 survival duration with, *Feb.*, 93-94
 single-agent, *Feb.*, 89-92
- Chest
 pain, assessment methodologies, *June*, 323-332
 radiography (*see* Radiography, chest)
 tomography in non-small cell lung cancer, *Feb.*, 77
- Cheyne-Stokes respiration: in congestive heart failure, *Aug.*, 494
- Chlorothiazide: in congestive heart failure, *Aug.*, 512
- Chlorpromazine: causing chronic hepatitis, *Mar.*, 150
- Cholecystokinin: in elderly, *July*, 449
- Cilastin: in COPD, *Sept.*, 574
- Cimetidine
 in gastroesophageal reflux, *June*, 371
 interactions with other drugs in ICU, *May*, 283
 in sclerosis, progressive systemic, *June*, 358
- Circulatory
 failure, classification of, *Aug.*, 474
 overload, classification of, *Aug.*, 474
- Cirrhosis: after autoimmune chronic active hepatitis, *Mar.*, 147
- Cisapride: in progressive systemic sclerosis, *June*, 358
- Cisplatin: causing hypomagnesemia, *Apr.*, 195
- Clavulanic acid: in COPD, *Sept.*, 574
- Clonidine: in postmenopausal elderly, *July*, 437

- Clotting effects: of hypermagnesiemia, *Apr.*, 208
- Cold liquids: causing esophageal motility disorders, *June*, 367
- Collagen vascular diseases: esophagus in, *June*, 358-359
- Coma: hyperosmolar nonketotic, as complication of total parenteral nutrition in ICU, *May*, 280
- Computed tomography (see Tomography, computed)
- Computer office system, *Jan.*, 9-51
- application programs, *Jan.*, 25-27
- applications, *Jan.*, 10-11, 27-44
- accounts receivable, *Jan.*, 32-35, 36
- ad hoc reporting, *Jan.*, 44
- collection management, *Jan.*, 39-41, 42
- data bases and files, *Jan.*, 27-28
- daily reporting, *Jan.*, 35-37, 38
- demand billing, *Jan.*, 35
- electronic claims submission, *Jan.*, 41
- financial management, *Jan.*, 29, 30
- introduction to, *Jan.*, 28-44
- medical records, *Jan.*, 41-43
- patient appointment scheduling, *Jan.*, 39, 40
- patient billing, *Jan.*, 29-32, 33, 34
- patient recalls, *Jan.*, 43
- referral tracking, *Jan.*, 43
- revenue distribution methods, *Jan.*, 37-39
- word processing, *Jan.*, 43
- automation of a mess leads to an automated mess, *Jan.*, 13
- complex medical office environment, *Jan.*, 9-10
- computer as means for survival, *Jan.*, 15
- computer as tool for financial management, *Jan.*, 13-14
- costs of, *Jan.*, 10
- establishing goals, *Jan.*, 12
- generation of additional revenue, *Jan.*, 14-15
- help features, *Jan.*, 44
- installation, *Jan.*, 44-48
- conversion of existing records, *Jan.*, 47
- identification of system profile changes, *Jan.*, 45, 46
- running first end-of-month processing, *Jan.*, 48
- site requirements, *Jan.*, 45-47
- training personnel, *Jan.*, 47
- justification, *Jan.*, 13-15
- more time for patients management, *Jan.*, 14
- preparation for, *Jan.*, 11-13
- selection process, *Jan.*, 15-21
- committee for, *Jan.*, 15
- consultants in, *Jan.*, 27
- defining requirements, *Jan.*, 16
- detail product demonstration, *Jan.*, 19
- request for proposal evaluation, *Jan.*, 18
- request for proposals, *Jan.*, 17-18
- site visits, *Jan.*, 18-19
- vendor contracts, *Jan.*, 20-21
- vendor selection, *Jan.*, 19
- vendors, *Jan.*, 19-20
- service, *Jan.*, 48-49
- software, *Jan.*, 10-11
- maintenance service, *Jan.*, 48-49
- telephone response support centers, *Jan.*, 49
- shared type, *Jan.*, 21-23
- stand-alone (in-house) type, *Jan.*, 23-25
- types of, *Jan.*, 21-27
- understanding requirements for automation, *Jan.*, 12-13
- vendor support, *Jan.*, 25-27
- Connective tissue disease: mixed, esophagus in, *June*, 358
- Contraction (see Heart, contraction)
- Contrast material causing renal complications in ICU, *May*, 268
- prevention of, *May*, 270
- COPD (see Lung, disease, obstructive, chronic)

- Coronary artery bypass surgery:
prognostic value of exercise
test after, *Nov.*, 723-725, 726
- Coronary artery disease
heart failure due to, congestive,
Aug., 507
- left main
post-test probability graphs
predicting, *Nov.*, 705
pretest probability graphs pre-
dicting, *Nov.*, 704
studies evaluating ability of ex-
ercise test to predict, *Nov.*,
702
- pathophysiology of, *Nov.*,
690-693
- Coronary heart disease (see Exer-
cise test, prognostic value of,
in coronary heart disease)
- Cor pulmonale
in blue bloaters, *Sept.* 565
hypoxic, chronic, pulmonary va-
sodilators in, *Sept.*, 578-580
- Corticosteroids
in COPD, *Sept.*, 571-573
exacerbations, acute infective,
Sept., 575
in hepatitis
autoimmune chronic active,
Mar., 146-147
autoimmune chronic active,
toxicity of, *Mar.*, 147-148
B, *Mar.*, 126
- Corticotropin (see ACTH)
- Cortisol
levels in Alzheimer's disease, *July*,
447
secretion, in elderly, *July*, 419
24-hour urinary free, in detection
of hypercortisolism, *Oct.*, 619
- Cortisone
acetate in Addison's disease, *Oct.*,
638
in adrenogenital syndromes, *Oct.*,
665
- Cost: of computer office system,
Jan., 10
- Cotrimoxazole: in COPD, *Sept.*, 574
- Cough: nocturnal, in congestive
heart failure, *Aug.*, 494
- Cranial irradiation: prophylactic, in
non-small cell lung cancer,
Feb., 87
- CREST syndrome: esophagus in,
June, 358
- Cricopharyngeal
achalasia, *June*, 362
hypertension, *June*, 362
hypotension, *June*, 362
myotomy in oropharyngeal dys-
phagia, *June*, 365-366
- Critically ill patients (see Intensive
care unit patients)
- Cryproheptadine: in Cushing's syn-
drome, *Oct.*, 626
- CT (see Tomography, computed)
- Cushing's disease (see Hypercorti-
solism, pituitary ACTH-de-
pendent)
- Cushing's syndrome, *Oct.*, 613-627
ACTH assay in, plasma, *Oct.*, 622
adrenal tumors causing
etiology of, *Oct.*, 614-615
treatment of, *Oct.*, 626-627
adrenalectomy in, bilateral, *Oct.*,
626
clinical features of, *Oct.*, 616-618
corticotropin releasing hormone
test in, *Oct.*, 623
cortisol test in, 24-hour urinary
free, *Oct.*, 619
CT scanning in, *Oct.*, 624
dexamethasone suppression test
in
high-dose, *Oct.*, 621-622
overnight, *Oct.*, 619-620
ectopic ACTH secretion causing
(see ACTH, secretion, ectopic,
causing Cushing's syndrome)
in elderly, *July*, 421
etiology of, *Oct.*, 613-615
localization of, *Oct.*, 623-625
hypertension in, *Oct.*, 616-617
laboratory features of, *Oct.*,
618-625
laboratory tests in, routine, *Oct.*,
618
metyrapone test in, *Oct.*,
622-623
myopathy of, *Oct.*, 616

Cushing's syndrome (*cont.*)
 neuropharmacotherapeutic
 agents in, *Oct.*, 626
 pituitary surgery in, transsphenoidal, *Oct.*, 625
 psychiatric disturbances in, *Oct.*, 617
 radiation in, conventional, *Oct.*, 625-626
 treatment of, *Oct.*, 625-627
 venous sampling of inferior petrosal sinus in, selective, *Oct.*, 624-625
 Cyclosporine: causing hypomagnesemia, *Apr.*, 196
 Cystic
 fibrosis, differential diagnosis, *Sept.*, 564
 parathyroid adenomatosis, *Dec.*, 760
 Cytology: sputum, detecting lung cancer, *Feb.*, 70

D

Death (*see* Mortality)
 Deglutition, *June*, 317-320
 esophageal stage, *June*, 319
 pharyngeal stage, *June*, 318-319
 voluntary stage, *June*, 318
 Deglutitive inhibition: in esophagus,
 schematic of, *June*, 326
 Delirium: acute, in ICU patients,
 therapy of, *May*, 285
 Delta virus, *Mar.*, 140-142
 antiviral therapy for, *Mar.*, 141-142
 Depression
 agitated, in ICU patients, therapy
 of, *May*, 285
 hyperparathyroidism and, primary, *Dec.*, 759
 hypomagnesemia and, *Apr.*, 190
 Dermatomyositis: esophagus in,
June, 362-363
 Desyrel: in nutcracker esophagus,
June, 354
 Dexamethasone
 in adrenogenital syndromes, *Oct.*, 665

in hyperaldosteronism, primary,
Oct., 651
 suppression test in Cushing's
 syndrome
 high-dose, *Oct.*, 621-622
 overnight, *Oct.*, 619-620
 Diabetes mellitus
 in elderly, *July*, 441-446
 complications of, acute, *July*, 442
 eye complications of, *July*, 442-443
 infections in, *July*, 443-444
 management of, *July*, 444-446
 management of, factors interfering with, *July*, 445
 nephropathy of, *July*, 443
 neuropathy of, *July*, 444
 prevalence of, *July*, 441
 esophageal motility disorders in,
June, 359-360
 heart failure due to, congestive,
Aug., 507
 ketoacidosis in, and hypermagnesemia, *Apr.*, 207
 type I, hypomagnesemia in, *Apr.*, 196
 Dialysis
 peritoneal
 complications in ICU, *May*, 273
 in hypermagnesemia, *Apr.*, 207
 ultrafiltration/equilibrium, determining free magnesium, *Apr.*, 188
 Diazepam: in psychiatric ICU syndromes, *May*, 286
 Diet: in congestive heart failure,
Aug., 508
 Digitalis
 in heart failure, congestive, *Aug.*, 511-514
 -induced arrhythmias, frequency of, *Aug.*, 515
 in tachycardia in ICU, multifocal atrial, *May*, 256
 Digoxin in ICU
 for atrial fibrillation, *May*, 251
 for atrial flutter, *May*, 252, 253
 for tachyarrhythmias, *May*, 249

- 1,25-Dihydroxyvitamin D
calcium regulation by, serum,
Dec., 751-753
level in primary hyperparathyroidism, *Dec.*, 764
- Dilatation, esophageal
in esophageal spasm, diffuse,
June, 351
forceful, in achalasia, *June*, 346
pneumatic, in achalasia, *June*,
344-345
- Diltiazem
in achalasia, *June*, 347
in nutcracker esophagus, *June*,
353
- Disopyramide in ICU
for atrial fibrillation, *May*, 251
for atrial flutter, *May*, 253
for tachyarrhythmias, *May*, 248
for tachycardia, atrioventricular
nodal reentrant, *May*, 255
- Diuretics
in heart failure, congestive, *Aug.*,
509-511
dosage and pharmacokinetic
characteristics of, *Aug.*, 512
hypomagnesemia due to, *Apr.*,
194-195
interactions with other drugs in
ICU, *May*, 283
preventing renal complications in
ICU, *May*, 270-271
renin activity response to, in hy-
peraldosteronism, *Oct.*, 644
thiazide (*see* Thiazides)
- Diverticulum: Zenker's, *June*, 362
- Dobutamine: in congestive heart
failure, *Aug.*, 515-516
- Dopamine
in heart failure, congestive, *Aug.*,
515-516
in prevention of renal complica-
tions in ICU, *May*, 270-271
- Doxycycline: in COPD, *Sept.*, 574
- Drinking: physiology of, *June*, 323
- Drug(s)
emergency, for tachyarrhythmias
in ICU, *May*, 248-249
in heart failure, congestive, *Aug.*,
509-519
hypermagnesemia due to, *Apr.*,
207
-induced adrenal insufficiency,
Oct., 631-632
-induced hepatitis, chronic, *Mar.*,
149-150
-induced hypercalcemia, *Dec.*,
779-780
interactions in ICU patients, *May*,
281-282, 283
magnesium excretion increase
due to, *Apr.*, 195
- Dynorphin: in elderly, *July*, 449
- Dysautonomia: familial, esophageal
motility disorders in, *June*,
364
- Dysphagia
hypomagnesemia and, *Apr.*, 190
oropharyngeal
abnormalities causing, *June*,
356
cricopharyngeal myotomy in,
June, 365-366
treatment of, *June*, 365-366
- Dysplasia: primary adrenocortical
nodular, *Oct.*, 615
- Dyspnea: in congestive heart failure,
Aug., 493-494
- Dystrophy
myotonic, esophagus in, *June*,
363
oculopharyngeal, esophagus in,
June, 363

E

- Eating: physiology of, *June*, 323
- ECG
exercise test (*see* Exercise test)
findings in ICU
in atrial fibrillation, *May*,
250-251
in atrial flutter, *May*, 251-252
in tachycardia, atrial multifocal,
May, 255
in tachycardia, atrioventricular
nodal reentrant, *May*, 254
in tachycardia, ventricular,
May, 256-258
hypomagnesemia and, *Apr.*, 191

- Echocardiography: in congestive heart failure, *Aug.*, 499-500
- Ectopy: ventricular, during passage of Swan-Ganz catheter in ICU, *May*, 262
- Edema: in congestive heart failure, *Aug.*, 495
- EHPD: in hypercalcemia, *Dec.*, 788-790
- Elderly
- Addison's disease in, *July*, 420
 - adrenal androgens in, *July*, 422-423
 - adrenal cortex in, *July*, 419-423
 - adrenal medulla in, *July*, 423-424
 - Alzheimer's disease in, hormonal alterations in, *July*, 447-448
 - anorexia in, *July*, 448-449
 - bone homeostasis in, *July*, 427-429
 - calcium homeostasis in, *July*, 427-429
 - cortisol secretion in, *July*, 419
 - Cushing's syndrome in, *July*, 421
 - diabetes in (see Diabetes mellitus, in elderly)
 - endocrinology in, *July*, 405-461
 - principles of, *July*, 407-408
- female
- estrogen action in, *July*, 436-437
 - hormonal changes in, postmenopausal, *July*, 436
 - menopause in (see Menopause in elderly)
 - reproductive system in, *July*, 436-439
- glucose tolerance in, *July*, 441-442
 - growth hormone in, *July*, 409-410
 - hormone levels in, serum, and response to provocative testing, *July*, 406
 - hyperparathyroidism in (see Hyperparathyroidism, in elderly)
 - hyperthyroidism in (see Hyperthyroidism, in elderly)
 - hypoparathyroidism in, *July*, 425
 - hypopituitarism in, *July*, 411-412
 - hypothalamic-pituitary-adrenal axis in, *July*, 420
 - hypothalamic-pituitary-testicular axis in, *July*, 431-432
 - hypothyroidism in (see Hypothyroidism in elderly)
- male
- androgen status in, *July*, 433
 - androgen therapy in, *July*, 435-436
 - hypogonadism in, *July*, 432-433
 - reproductive hormone changes in, *July*, 431
 - reproductive physiology in, *July*, 431-436
 - sexual function in, *July*, 433-435
 - malnutrition in, causes of, *July*, 448
 - osteopenia in (see Osteopenia, in elderly)
 - parathyroid dysfunction in, *July*, 424-427
 - parathyroid hormone physiology in, *July*, 424-425
 - pituitary in, anterior, *July*, 409-412
 - pituitary function testing in, dynamic, *July*, 410-411
 - polyglandular failure in, *July*, 446-447
 - somatomedin C in, *July*, 409-410
 - sympathetic nervous system in, *July*, 423-424
 - thyroid anatomy in, *July*, 412
 - thyroid cancer in, *July*, 418
 - thyroid disease in, *July*, 412-418
 - thyroid function tests in, *July*, 412-414
 - thyroid physiology alterations in, *July*, 413
 - water metabolism in, *July*, 439-441
- Electrocardiography (see ECG)
- Electrode: ion-selective, for determining free magnesium, *Apr.*, 187
- Emphysema, *Sept.*, 554
- CT in, *Sept.*, 561
 - definition of, *Sept.*, 551

- pathogenesis of, *Sept.*, 555-556
radiology in, *Sept.*, 559-560
- Enalapril
in cor pulmonale, chronic hypoxic, *Sept.*, 579, 580
in heart failure, congestive, *Aug.*, 521
- Endocrine disorders: nonparathyroid, causing hypercalcemia, *Dec.*, 776-777
- Endocrinology, in elderly, *July*, 405-461
principles of, *July*, 407-408
- Endometrial adenocarcinoma: and estrogen therapy, in elderly, *July*, 438
- Endomyocardial biopsy: in congestive heart failure, *Aug.*, 500, 501
- Endoscopy
in achalasia, *June*, 341
in gastroesophageal reflux, *June*, 369-370
- Endotracheal intubation: causing laryngotracheal injury, in ICU, *May*, 234-238
- Epinephrine: in elderly, *July*, 423
- Erythrocytes, magnesium in, *Apr.*, 174
assessment of, *Apr.*, 184
- Erythromycin: in COPD, *Sept.*, 574
- Esophagoscopy: in achalasia, *June*, 343
- Esophagram, barium
in achalasia, *June*, 341, 342
double-contrast, in gastroesophageal reflux, *June*, 369
- Esophagus
anatomy, *June*, 307-312
biopsy in achalasia, *June*, 343
bougienage in nutcracker esophagus, *June*, 353
deglutitive inhibition in, schematic of, *June*, 326
function, physiology of, *June*, 312-323
gastroesophageal reflux (see Gastroesophageal reflux)
histology in gastroesophageal reflux, *June*, 370
innervation of, extrinsic, *June*, 309
motility
assessment, methodologies of, *June*, 323-332
disorders (see below)
schematic of, *June*, 330
motility disorders, *June*, 307-389
in amyloidosis, systemic, *June*, 366
in cerebral vascular accident, *June*, 364
in Chagas' disease, *June*, 360
classification of, *June*, 334-372
clinical conditions associated with, *June*, 335
clinical presentations, *June*, 333-334
cold liquid ingestion causing, *June*, 367
in collagen vascular diseases, *June*, 358-359
in connective tissue disease, mixed, *June*, 358
in CREST syndrome, *June*, 358
in dermatomyositis, *June*, 362-363
in diabetes mellitus, *June*, 359-360
in dysautonomia, familial, *June*, 364
exercise and, *June*, 367
future work in, *June*, 372
hemodialysis and, chronic, *June*, 366
hiatal hernia and, *June*, 366
in intestinal pseudo-obstruction, chronic idiopathic, *June*, 361
in lupus erythematosus, systemic, *June*, 358-359
mechanisms of, *June*, 333
miscellaneous, *June*, 366-367
in myasthenia gravis, *June*, 363-364
in myotonic dystrophy, *June*, 363
nonspecific, *June*, 355
in oculopharyngeal dystrophy, *June*, 363

Esophagus (*cont.*)

- in palsy, chronic progressive bulbar, *June*, 364
- in palsy, pseudobulbar, *June*, 364
- in Parkinson's disease, *June*, 364
- in peripheral nerve disease, *June*, 364-365
- in poliomyelitis, bulbar, *June*, 364
- in polymyositis, *June*, 362-363
- in polyneuropathy, familial amyloid, *June*, 366
- primary, *June*, 335-355
- primary, manometric criteria for, *June*, 339
- primary, manometric tracings in, *June*, 336-338
- in rheumatoid arthritis, *June*, 359
- in sclerosis, multiple, *June*, 364
- in sclerosis, progressive systemic (*see* Sclerosis, systemic, progressive)
- secondary, *June*, 355-366
- in Sjögren's syndrome, primary, *June*, 359
- in striated muscle dysfunction, *June*, 361-366
- muscular hypertrophy, idiopathic diffuse, *June*, 366-367
- nutcracker, *June*, 352-354
 - clinical features of, *June*, 352
 - diagnosis of, *June*, 352-353
 - etiology of, *June*, 352
 - pathogenesis of, *June*, 352
 - treatment of, *June*, 353-354
- "presbyesophagus," *June*, 360-361
- sclerotherapy, *June*, 367
- spasm, diffuse, *June*, 347-352
 - association with achalasia, *June*, 349
 - clinical features of, *June*, 348
 - diagnosis of, *June*, 348-349
 - etiology of, *June*, 348
 - pathophysiology of, *June*, 348
 - treatment of, *June*, 350-352

- sphincter, lower, hypertensive, *June*, 354-355
 - clinical features of, *June*, 354
 - diagnosis of, *June*, 354
 - treatment of, *June*, 354-355
- sphincter, lower, pressure decreased, agents producing, *June*, 316
- in healthy subjects, *June*, 329
- increased, agents producing, *June*, 315
- sphincter, lower, vagal inhibitory pathway to, schematic of, *June*, 325
- transit assessment, methodologies of, *June*, 323-332
- Estradiol: in hyperparathyroidism, in elderly, *July*, 427
- Estrogen
 - action in elderly, *July*, 436-437
 - hypercalcemia due to, *Dec.*, 779-780
 - in osteopenia, in elderly, *July*, 430-431
- therapy
 - in elderly, *July*, 437-439
 - in hyperparathyroidism, primary, in postmenopausal women, *Dec.*, 771
- Ethacrynic acid in congestive heart failure, *Aug.*, 510
- dosage and pharmacokinetic characteristics of, *Aug.*, 512
- Ethinyl estradiol: in hyperparathyroidism, in elderly, *July*, 427
- Etidronate: in hypercalcemia, *Dec.*, 788-790
- Etomidate: causing adrenal insufficiency, *Oct.*, 632
- Exercise: and esophageal motility disorders, *June*, 367
- Exercise test
 - in heart failure, congestive, *Aug.*, 500-505
 - induced ventricular arrhythmia, *Nov.*, 719-720
 - induced ventricular contractions, example of, *Nov.*, 720-722
 - induced ventricular tachycardia, example of, *Nov.*, 720-722

prognostic value of, *Nov.*, 689-735
 in apparently healthy individuals, *Nov.*, 725-727
 in coronary heart disease, stable, *Nov.*, 699-725
 in coronary heart disease, stable, cardiac end points in, *Nov.*, 712-722
 in coronary heart disease, stable, for predicting angiographic findings, *Nov.*, 700-706
 in coronary heart disease, stable, for predicting angiographic findings, examples of, *Nov.*, 703-706
 example of predicting cardiac events, *Nov.*, 717-719
 examples of elevation over Q waves, *Nov.*, 691-693
 hypotension and, exercise-induced, *Nov.*, 706-711
 hypotension and, exercise-induced, examples of, *Nov.*, 708-712, 713, 714
 after myocardial infarction, *Nov.*, 694-699
 after myocardial infarction, examples of, *Nov.*, 696-699
 predicting coronary artery disease, left main, studies evaluating ability of test, *Nov.*, 702
 in predicting improved survival with coronary bypass surgery vs. medical therapy, *Nov.*, 723-725, 726
 ventricular arrhythmia induced by, *Nov.*, 719-720
 Expiratory flow, peak
 in asthma, bronchial, *Sept.*, 558
 in COPD, *Sept.*, 558
 after COPD treatment, *Sept.*, 573
 Eye complications: of diabetes, in elderly, *July*, 442-443

F

Famotidine
 in gastroesophageal reflux, *June*, 371

in sclerosis, progressive systemic, *June*, 358
 Fear: in ICU patients, therapy of, *May*, 285
 Fibrillation (*see* Intensive care unit patients, atrial fibrillation in)
 Fibrosis: cystic, differential diagnosis, *Sept.*, 564
 Financial management: office computer for, *Jan.*, 13-14, 29, 30
 9a-Fludrocortisone: in hyporenemic hypoaldosteronism, *Oct.*, 657
 Fluids: body, magnesium distribution in, *Apr.*, 173-174
 Fluoroscopy: in achalasia, *June*, 341
 Flutter (*see* Intensive care unit patients, atrial flutter in)
 Food: magnesium in, *Apr.*, 176-177
 Fungal Addison's disease, *Oct.*, 629-630
 Furosemide in congestive heart failure, *Aug.*, 510
 dosage and pharmacokinetic characteristics of, *Aug.*, 512

G

Galactorrhea: in Addison's disease, *Oct.*, 634
 Gallium nitrate: in hypercalcemia, *Dec.*, 791
 Gastroesophageal reflux, *June*, 367-372
 pathogenesis of, *June*, 368
 testing for, *June*, 369-370
 treatment of, *June*, 370-372
 Gastrointestinal
 absorption of calcium, excessive, causing hypercalcemia, therapy of, *Dec.*, 791-792
 complications in respiratory ICU, *May*, 238-239
 symptoms of Addison's disease, *Oct.*, 633
 tract in primary hyperparathyroidism, *Dec.*, 759
 Genetics: of 21-hydroxylase deficiency, *Oct.*, 662-663
 Geriatric (*see* Elderly)

Glucocorticoid(s)
 in hypercalcemia, *Dec.*, 792
 -suppressible hyperaldosteronism, *Oct.*, 640
 Glucose
 levels in Alzheimer's disease, *July*, 447
 tolerance of aging, *July*, 441-442
 Gonadal symptoms: in Addison's disease, *Oct.*, 633-634
 Gout: and primary hyperparathyroidism, *Dec.*, 759
 Granulomatous diseases: causing hypercalcemia, *Dec.*, 778-779
 Growth
 factor, transforming-, in humoral hypercalcemia of malignancy, *Dec.*, 775
 hormone
 in Alzheimer's disease, *July*, 447
 in elderly, *July*, 409-410

H

Haloperidol: in psychiatric ICU syndromes, *May*, 286
 Halothane: causing chronic hepatitis, *Mar.*, 150
 Heart
 asthma, *Aug.*, 494
 complications in ICU, *May*, 250-264
 contraction
 cellular basis and derangement in heart failure, *Aug.*, 477-484
 mechanics in normal and failing ventricles, *Aug.*, 485-488
 disease, coronary (see Exercise test, prognostic value of, in coronary heart disease)
 enlargement in congestive heart failure, *Aug.*, 497
 failure, congestive, *Aug.*, 473-536
 antiarrhythmics in, *Aug.*, 524-525
 anticoagulants in, *Aug.*, 525
 beta-adrenergic agonists in, *Aug.*, 517-518
 beta blockers in, *Aug.*, 518-519

blood volume regulation in, *Aug.*, 488-493
 clinical manifestations of, *Aug.*, 493-506
 contraction derangement in, *Aug.*, 477-484
 diagnosis of, differential, *Aug.*, 505-506
 digitalis in, *Aug.*, 511-514
 diuretics in, *Aug.*, 509-511
 diuretics in, dosage and pharmacokinetic characteristics of, *Aug.*, 512
 epidemiology of, *Aug.*, 475-477
 exercise testing in, *Aug.*, 500-505
 heart transplantation in, *Aug.*, 525-527
 inotropic support in, conventional, *Aug.*, 511-517
 inotropic support in, newer agents, *Aug.*, 517-519
 inotropic support in, standard intravenous agents, *Aug.*, 514-516
 neurohumoral compensations in, *Aug.*, 492
 pharmacologic measures in, *Aug.*, 509-519
 phosphodiesterase inhibitors in, *Aug.*, 517
 prevention of, *Aug.*, 506-508
 renin-angiotensin-aldosterone system in, *Aug.*, 489
 signs of, *Aug.*, 493-498
 special investigations in, *Aug.*, 498-500
 symptoms of, *Aug.*, 493-498
 treatment of, *Aug.*, 506-527
 treatment of, conservative, *Aug.*, 508
 vasodilators in (see Vasodilators, in heart failure, congestive)
 manifestations
 of hypermagnesemia, *Apr.*, 206
 of hypomagnesemia, *Apr.*, 190-191
 muscle, diagram of, *Aug.*, 479

- "pump" failure, overall, causes of, *Aug.*, 476
- transplantation in congestive heart failure, *Aug.*, 525-527
- Hemodialysis
- chronic, and esophageal motility disorders, *June*, 366
 - complications in ICU, *May*, 272
 - in hypermagnesemia, *Apr.*, 207
- Hemodynamic monitoring (*see* Intensive care unit patients, hemodynamic monitoring complications in)
- Hemoptysis: in congestive heart failure, *Aug.*, 494-495
- Hemorrhage
- adrenal, causing Addison's disease, *Oct.*, 630-631
 - gastrointestinal, in respiratory ICU patients, *May*, 238-239
- Hemorrhagic shock causing renal complications in ICU, *May*, 267
- prevention of, *May*, 270
- Hepatitis
- autoimmune chronic active, *Mar.*, 143-149
 - azathioprine in, toxicity of, *Mar.*, 147-148
 - corticosteroids in, toxicity of, *Mar.*, 147-148
 - patient monitoring and follow-up, *Mar.*, 148-149
 - therapeutic regimens, *Mar.*, 146-147
 - therapy of, *Mar.*, 145-146
 - autoimmune lupoid (*see* autoimmune chronic active)
- B, *Mar.*, 123-140
- acyclovir in, *Mar.*, 134-135
 - adenine arabinoside and adenine arabinoside monophosphate in, *Mar.*, 135-136
 - antiviral therapy for, *Mar.*, 125-127
 - interferon in (*see* Interferon, in hepatitis B)
 - liver disease in, hypothetical immunopathogenesis of, *Mar.*, 124
 - neonatal carrier state, *Mar.*, 125
 - pathogenesis of, *Mar.*, 123-140
 - prednisone withdrawal in, *Mar.*, 136-138
 - treatment of, *Mar.*, 123-140
 - treatment of, combination, *Mar.*, 139-140
- chronic, *Mar.*, 117-159
- active, *Mar.*, 120
 - active, autoimmune (*see* Hepatitis, autoimmune chronic active above)
 - definition of *Mar.*, 117-119
 - diagnosis of, *Mar.*, 122
 - drug-induced, *Mar.*, 149-150
 - liver transplant in, *Mar.*, 151
 - pathogenesis of, *Mar.*, 123-150
 - pathology of, *Mar.*, 119-122
 - persistent, *Mar.*, 119-120
 - treatment of, *Mar.*, 123-150
- D virus, *Mar.*, 140-142
- antiviral therapy for, *Mar.*, 141-142
 - non-A, non-B, *Mar.*, 142-143
 - antiviral therapy for, *Mar.*, 143
- Hernia: hiatal, and esophageal motility disorders, *June*, 366
- Hiatal hernia: and esophageal motility disorders, *June*, 366
- Histomorphometry: bone, in primary hyperparathyroidism, *Dec.*, 765
- Histoplasmosis: causing Addison's disease, *Oct.*, 629
- Hormone
- adrenocorticotrophic (*see* ACTH)
 - alterations in Alzheimer's disease, *July*, 447-448
 - changes, postmenopausal, in elderly, *July*, 436
 - growth (*see* Growth, hormone)
 - milieu in 21-hydroxylase deficiency, *Oct.*, 660-661
 - parathyroid (*see* Parathyroid, hormone)
 - reproductive, in elderly male, *July*, 431
 - serum levels associated with aging, and response to provocative testing, *July*, 406

Hormone (*cont.*)

thyroid-stimulating, in Alzheimer's disease, *July*, 447

H₂-receptor antagonists: in primary hyperparathyroidism, *Dec.*, 770

Hydralazine

in cor pulmonale, chronic hypoxic, *Sept.*, 579

in esophageal spasm, diffuse, *June*, 350-351

in heart failure, congestive, *Aug.*, 520

Hydrochlorothiazide: in congestive heart failure, *Aug.*, 512

Hydrocortisone

in adrenogenital syndromes, *Oct.*, 665

18-, plasma levels, in primary hyperaldosteronism, *Oct.*, 647-648

hemisuccinate in Addison's disease, *Oct.*, 638

11 β -Hydroxylase deficiency, *Oct.*, 663-664

prognosis of, *Oct.*, 664

treatment of, *Oct.*, 664-665

21-Hydroxylase deficiency, *Oct.*, 659-663

clinical features of, *Oct.*, 661

diagnosis of, *Oct.*, 661-662

differential, *Oct.*, 662

genetics of, *Oct.*, 662-663

hormonal milieu in, *Oct.*, 660-661

incidence of, *Oct.*, 660

prognosis of, *Oct.*, 664

treatment of, *Oct.*, 664-665

types of, *Oct.*, 660

Hyperaldosteronism

glucocorticoid-suppressible, *Oct.*, 640

hypomagnesemia in, *Apr.*, 197

idiopathic, *Oct.*, 639-640

distinction between aldosterone-producing adenoma and, *Oct.*, 645-646

laboratory confirmation of, *Oct.*, 645

normotensive, *Oct.*, 642

primary, *Oct.*, 639-651

aldosterone-producing adenoma causing, *Oct.*, 639

aldosterone response to standing posture between 8 AM and noon in, *Oct.*, 646-647

clinical features of, *Oct.*, 642-643

diagnosis of, differential, *Oct.*, 649, 650

diagnosis of, laboratory, *Oct.*, 643-649

etiology of, *Oct.*, 639-640

18-hydroxycorticosterone levels in, plasma, *Oct.*, 647-648

localizational procedures, *Oct.*, 648

pathophysiology of, *Oct.*, 640-642

plasma renin activity response to posture and diuretic in, *Oct.*, 644

saline infusion test in, *Oct.*, 644

screening for, *Oct.*, 643-645

treatment of, *Oct.*, 649-651

venous effluent study in, bilateral, *Oct.*, 648-649

Hypercalcemia, *Dec.*, 749-799

adrenal insufficiency causing, *Dec.*, 776-777

antiestrogens causing, *Dec.*, 779-780

bisphosphonates in, *Dec.*, 788-790

bone resorption inhibiting agents in, *Dec.*, 787-791

calcitonin in, *Dec.*, 790

causes of, *Dec.*, 754, 775-783

features of, *Dec.*, 753-783

multiple, in same individual, *Dec.*, 782-783

clinical features of, *Dec.*, 783-785

differential diagnosis of, *Dec.*, 753-783

endocrine disorders causing, nonparathyroid, *Dec.*, 776-777

estrogen causing, *Dec.*, 779-780

gastrointestinal absorption of calcium causing, excessive, therapy of, *Dec.*, 791-792

- granulomatous diseases causing, *Dec.*, 778-779
- hyperparathyroidism causing (*see* Hyperparathyroidism, primary)
- hypocalciuric, familial, *Dec.*, 780-781
- hypomagnesemia and, *Apr.*, 197
- immobilization, *Dec.*, 781
- lithium carbonate causing, *Dec.*, 779
- of malignancy, *Dec.*, 771-775
- associated peptide, *Dec.*, 773-775
- humoral, *Dec.*, 772-773
- humoral, agents responsible for, *Dec.*, 775
- medication-induced, *Dec.*, 779-780
- mithramycin in, *Dec.*, 788
- parenteral nutrition and, *Dec.*, 781-782
- pheochromocytoma causing, *Dec.*, 776
- phosphate in, *Dec.*, 790
- prostaglandin inhibitors in, *Dec.*, 790-791
- in renal disease, acute and chronic, *Dec.*, 782
- therapy for, *Dec.*, 785-792
- general measures, *Dec.*, 786-787
- principles of, *Dec.*, 785-786
- specific measures, *Dec.*, 787-792
- thiazide diuretics causing, *Dec.*, 779
- thyrotoxicosis causing, *Dec.*, 776
- VIP-omas causing, *Dec.*, 777
- vitamin A toxicity causing, *Dec.*, 780
- vitamin D toxicity causing, *Dec.*, 777-778
- Hypercortisolism**
(*See also* Cushing's syndrome)
etiology of, laboratory tests establishing, *Oct.*, 620-623
- pituitary ACTH-dependent
etiology of, *Oct.*, 613-614
- treatment of, *Oct.*, 625-626
- screening for, *Oct.*, 618-620
- Hypermagnesemia, *Apr.*, 205-208
- causes of, *Apr.*, 206-207
- diagnosis of, *Apr.*, 207
- effects of, *Apr.*, 208
- manifestations of, *Apr.*, 205-206
- treatment of, *Apr.*, 207
- Hypernatremia: in elderly, *July*, 439-440
- Hyperosmolar nonketotic coma: as complication of total parenteral nutrition in ICU, *May*, 280
- Hyperparathyroidism**
in elderly, *July*, 425-427
- clinical presentation, *July*, 425-426
- diagnosis of, laboratory, *July*, 426
- prevalence of, *July*, 425
- treatment of, medical, *July*, 427
- treatment of, surgical, *July*, 426-427
- primary, *Dec.*, 754-771
- bone disease in, radiographic, *Dec.*, 757
- bone in, histological appearance of, *Dec.*, 758
- clinical forms of, *Dec.*, 759-761
- diagnosis of, *Dec.*, 761-765
- evaluation of, *Dec.*, 761-765
- hypomagnesemia in, *Apr.*, 197
- medical management of, *Dec.*, 770-771
- normocalcemic, *Dec.*, 761
- preoperative localization of parathyroid adenoma in, *Dec.*, 767-770
- signs of, *Dec.*, 756-759
- surgery in, *Dec.*, 765-767
- symptoms of, *Dec.*, 756-759
- treatment of, *Dec.*, 765-771
- Hyperplasia (*see* Adrenal, hyperplasia)
- Hypertension**
cricopharyngeal, *June*, 362
- in Cushing's syndrome, *Oct.*, 616-617
- heart failure and, congestive, *Aug.*, 506-507
- in hyperaldosteronism, *Oct.*, 642

Hypertension (*cont.*)

hyperparathyroidism and, primary, *Dec.*, 759

hypomagnesemia and, *Apr.*, 203-204

pulmonary

primary, differential diagnosis, *Sept.*, 565

thromboembolic, chronic, differential diagnosis, *Sept.*, 565

Hypertensive esophageal sphincter

(see Esophagus, sphincter, lower, hypertensive)

Hyperthyroidism

in elderly, *July*, 415-418

clinical presentation of, *July*, 415-416

etiology of, *July*, 415

laboratory diagnosis of, *July*, 416-418

prevalence of, *July*, 415

treatment of, *July*, 418

hypomagnesemia in, *Apr.*, 197

Hypertrophy: idiopathic diffuse esophageal muscular, *June*, 366-367

Hypoaldosteronism

hyporeninemic, *Oct.*, 651-657

acidosis in, *Oct.*, 654-655

clinical features of, *Oct.*, 655-656

diagnosis of, laboratory, *Oct.*, 656-657

etiology of, *Oct.*, 652

hyporeninemia in, pathogenesis of, *Oct.*, 652-653

hypoaldosteronism in, pathogenesis of, *Oct.*, 653-654

pathogenesis of, *Oct.*, 652-655

treatment of, *Oct.*, 657

selective, *Oct.*, 651-657

etiology of, *Oct.*, 651

Hypocalcemia: and hypomagnesemia, *Apr.*, 191-192

Hypocalciuric hypercalcemia: familial, *Dec.*, 780-781

Hypogonadism: in elderly male, *July*, 432-433

Hypokalemia

after diuretics in congestive heart failure, *Aug.*, 511

in hyperaldosteronism, *Oct.*, 642-643

hypomagnesemia and, *Apr.*, 191

Hypomagnesemia, *Apr.*, 188-205

absorption reduction causing, *Apr.*, 193-194

atherosclerosis and, *Apr.*, 201

cancer and, *Apr.*, 204

causes of, *Apr.*, 192-198

diagnosis of, *Apr.*, 198-199

effect of, *Apr.*, 200-205

excretion increase causing, *Apr.*, 194-196

hypertension and, *Apr.*, 203-204

intake reduction causing, *Apr.*, 193

manifestations of, *Apr.*, 189-192

cardiac, *Apr.*, 190-191

CNS, *Apr.*, 190

metabolic, *Apr.*, 191-192

neuromuscular, *Apr.*, 190

myocardial infarction and, *Apr.*, 202-203

premenstrual syndrome and, *Apr.*, 205

redistribution causing, *Apr.*, 194

renal stones and, *Apr.*, 204-205

treatment of, *Apr.*, 199-200

Hyponatremia: in elderly, *July*, 440-441

Hypoparathyroidism: in elderly, *July*, 425

Hypopharynx, *June*, 308

Hypopituitarism: in elderly, *July*, 411-412

Hyporeninemic hypoaldosteronism (see Hypoaldosteronism, hyporeninemic)

Hypotension

in Addison's disease, *Oct.*, 633

cricopharyngeal, *June*, 362

exercise-induced, *Nov.*, 706-711

examples of, *Nov.*, 708-712, 713, 714

meal-induced, in elderly, *July*, 424

renal complications in ICU due to, *May*, 267

- Hypothalamic
 - pituitary adrenal axis, in elderly, *July*, 420
 - pituitary-testicular axis, in elderly, *July*, 431-432
- Hypothyroidism in elderly, *July*, 414-415
 - clinical manifestations of, *July*, 415
 - etiology of, *July*, 414
 - prevalence of, *July*, 414
 - treatment of, *July*, 418
- Hypoxic cor pulmonale: chronic, pulmonary vasodilators in, *Sept.*, 578-580

I

- ICU patients (*see* Intensive care unit patients)
- Imaging
 - iodcholesterol, in primary hyperaldosteronism, *Oct.*, 648
 - magnetic resonance (*see* Magnetic resonance, imaging)
- Imipenem: in COPD, *Sept.*, 574
- Immobilization hypercalcemia, *Dec.*, 781
- Immune modulation: in autoimmune chronic active hepatitis, *Mar.*, 146
- Impotence: in elderly, *July*, 434-435
- Infarction
 - myocardial (*see* Myocardial infarction)
 - pulmonary, due to Swan-Ganz catheter in ICU, *May*, 263
- Infections
 - Addison's disease due to, *Oct.*, 629-630
 - as complication of parenteral nutrition in ICU, *May*, 280
 - as complication of Swan-Ganz catheter in ICU, *May*, 263
 - diabetic, in elderly, *July*, 443-444
 - nosocomial, in ICU, *May*, 264-265
 - risk, etiology, and therapy of, *May*, 266
- Influenza: in COPD, prophylaxis of, *Sept.*, 576-577
- Innervation: extrinsic, of pharynx and esophagus, *June*, 309
- Inotropic support (*see* Heart failure, congestive, inotropic support in)
- Inspiratory muscle fatigue: in COPD, *Sept.*, 587-589
- Insulin levels: in Alzheimer's disease, *July*, 447
- Intensive care unit patients
 - acid-base disturbances in, *May*, 273-276
 - acidosis in, metabolic, *May*, 276
 - alkalosis in, metabolic, *May*, 273-276
 - arrhythmias in, *May*, 250-258
 - atrial fibrillation in, *May*, 250-251
 - ECG findings, *May*, 250-251
 - predisposing factors, *May*, 251
 - treatment, *May*, 251
 - atrial flutter in, *May*, 251-253
 - ECG findings, *May*, 251-252
 - predisposing factors, *May*, 252
 - treatment, *May*, 252-253
 - cardiac complications in, *May*, 250-264
 - complications in, *May*, 233-293
 - dialysis complications in, peritoneal, *May*, 273
 - drug interactions in, *May*, 281-282, 283
 - gastrointestinal complications in, *May*, 238-239
 - hemodialysis complications in, *May*, 272
 - hemodynamic monitoring complications in, *May*, 258-264
 - during catheter insertion, *May*, 261-262
 - during catheter passage, *May*, 262
 - while catheter is in place, *May*, 262-264
 - pulmonary artery wedge pressure as reflection of left ventricular end-diastolic pressure, *May*, 259-260
 - technical aspects of pressure measurement, *May*, 259

- Intensive care unit patients (*cont.*)
- laryngotracheal injury due to endotracheal intubation in, *May*, 234-238
 - mechanical ventilation in
 - preventing errors of, *May*, 241-250
 - strategies for discontinuation of, *May*, 243
 - weaning from, *May*, 244
 - weaning from, causes of failure, *May*, 245-247
 - weaning from, intermittent mandatory ventilation for, *May*, 244-245
 - weaning from pressure support ventilation for, *May*, 245
 - weaning from, weaning off PEEP, *May*, 245
 - nosocomial infection in, *May*, 264-265
 - risk, etiology, and therapy of, *May*, 266
 - nutritional management complications in, *May*, 276-281
 - nutritional support complications in, *May*, 277-281
 - postextubation care, *May*, 247, 250
 - psychiatric complications in, *May*, 282-286
 - psychiatric syndromes in
 - etiology of, *May*, 282-284
 - therapy of, *May*, 285-286
 - pulmonary barotrauma in, *May*, 240
 - pulmonary complications in, *May*, 233-250
 - pulmonary thromboemboli in, *May*, 239-240
 - renal complications in, *May*, 265, 267-273
 - etiology of, *May*, 267-269
 - pathophysiology of, *May*, 267-269
 - prevention of, *May*, 269-271
 - treatment of, *May*, 271-273
 - respiratory failure in, acute causes of, *May*, 234
 - complications of, *May*, 233-241
 - complications of, importance of chest roentgenogram in, *May*, 242
 - roentgenograms related to, *May*, 236, 237, 238
 - starvation in, *May*, 277, 278
 - tachyarrhythmias in, emergency drugs for, *May*, 248-249
 - tachycardia in, atrial multifocal, *May*, 255-256
 - ECG findings, *May*, 255
 - predisposing factors, *May*, 255
 - treatment, *May*, 255-256
 - tachycardia in, atrioventricular nodal reentrant
 - ECG features, *May*, 254
 - mechanism of, *May*, 254-254
 - predisposing factors, *May*, 254
 - treatment, *May*, 254-255
 - tachycardia in, supraventricular, paroxysmal, *May*, 253-255
 - definition of, *May*, 253
 - tachycardia in, ventricular, *May*, 256-258
 - definition, *May*, 256
 - ECG features, *May*, 256-258
 - treatment, *May*, 258
 - ventilator settings in
 - initial, in acute respiratory failure, *May*, 242-243
 - optimizing, *May*, 241-242
- Interferon
- alpha-, in hepatitis D, *Mar.*, 142
 - in hepatitis B, *Mar.*, 127-134
 - therapeutic trials, *Mar.*, 130-134
 - toxicity of, *Mar.*, 134
- Interleukin 2: in hepatitis B, *Mar.*, 138
- Intestine
- (*See also* Gastrointestinal)
- pseudo-obstruction, chronic idiopathic, esophagus in, *June*, 361
- Intubation: endotracheal, causing laryngotracheal injury in ICU, *May*, 234-238
- Iodocholesterol imaging: in primary hyperaldosteronism, *Oct.*, 648

Ion-selective electrode: for determining free magnesium, *Apr.*, 187

Ipratropium in COPD
with β_2 -agonists, *Sept.*, 570-571
with β_2 -agonist and theophylline, *Sept.*, 571

Irradiation (see Radiation)

Isoniazid-induced chronic hepatitis, *Mar.*, 150

Isosorbide dinitrate: in congestive heart failure, *Aug.*, 519-520

Isotope studies: of magnesium, *Apr.*, 186

K

Ketoacidosis: diabetic, and hypermagnesemia, *Apr.*, 207

Ketoconazole
adrenal insufficiency due to, *Oct.*, 631-632
in Cushing's syndrome, *Oct.*, 627

Kidney
complications in ICU (see Intensive care unit patients, renal complications in)

disease
acute and chronic, hypercalcemia in, *Dec.*, 782
hypomagnesemia and, *Apr.*, 196-197
excretion of magnesium, *Apr.*, 186
failure causing hypermagnesemia, *Apr.*, 206-207
stones (see Nephrolithiasis)
transplantation, hypercalcemia after, *Dec.*, 782

L

Lactation: excessive, causing hypomagnesemia, *Apr.*, 198

Laryngotracheal injury: due to endotracheal intubation, in ICU, *May*, 234-238

Levamisole in hepatitis B, *Mar.*, 126, 138
Mar., 142

Lidocaine
prophylactic, prior to Swan-Ganz catheter insertion, *May*, 262
in tachyarrhythmias, in ICU, *May*, 248
in tachycardia, ventricular, in ICU, *May*, 258

Liquids: cold, causing esophageal motility disorders, *June*, 367

Lithium carbonate: causing hypercalcemia, *Dec.*, 779

Liver
abscess, pyogenic, after interferon in hepatitis B, *Mar.*, 134

disease
chronic active, hepatic sinusoid in, *Mar.*, 118
in hepatitis B, hypothetical immunopathogenesis of, *Mar.*, 124
sinusoid in chronic active liver disease, *Mar.*, 118
transplantation in chronic hepatitis, *Mar.*, 151

Lung
(See also Pulmonary)
cancer (see Cancer, lung)
disease, obstructive, chronic, *Sept.*, 549-599
 β_2 -agonists in, *Sept.*, 569-570
bronchiectasis differentiated from, *Sept.*, 563-564
bronchitis differentiated from, chronic asthmatic, *Sept.*, 565-566
bronchodilators in, *Sept.*, 568-573
clinical features of, *Sept.*, 556-557
corticosteroids in, *Sept.*, 571-573
cystic fibrosis differentiated from, *Sept.*, 564
definitions related to, *Sept.*, 549-554
diagnosis of, differential, *Sept.*, 563-566
exacerbations of, acute, controlled oxygen therapy in, *Sept.*, 575-576

Lung (*cont.*)

- exacerbations of, acute, infective, antimicrobials in, *Sept.*, 573-575
 - influenza prophylaxis in, *Sept.*, 576-577
 - inspiratory muscle fatigue in, *Sept.*, 587-589
 - nutrition in, *Sept.*, 577-578
 - oxygen therapy in, long-term domiciliary, *Sept.*, 580-583
 - peak expiratory flow in, *Sept.*, 558
 - physical examination in, *Sept.*, 556-557
 - pulmonary hypertension differentiated from, chronic thromboembolic, *Sept.*, 565
 - pulmonary hypertension differentiated from, primary, *Sept.*, 565
 - respiratory function studies in, *Sept.*, 557-559
 - respiratory infections in, prophylaxis of, *Sept.*, 576-577
 - sleep-disordered breathing in, *Sept.*, 583-587
 - smoking cessation in, *Sept.*, 566-568
 - Streptococcus pneumoniae* prophylaxis in, *Sept.*, 577
 - theophylline in, *Sept.*, 568-569
 - treatment of, *Sept.*, 566-583
 - disease, obstructive, generalized, *Sept.*, 549
- Lupoid hepatitis, autoimmune (see Hepatitis, autoimmune chronic active)
- Lupus erythematosus: systemic, esophagus in, *June*, 358-359
- Lymphoma: and hypercalcemia, *Dec.*, 775

M

Magnesium

- absorption of, *Apr.*, 178
- reduced, causing hypomagnesemia, *Apr.*, 193-194

- balance studies, *Apr.*, 185
- in body fluids, *Apr.*, 173-174
- deficiency (see Hypomagnesemia)
- distribution of, *Apr.*, 173-175
- excess (see Hypermagnesemia)
- excretion of, *Apr.*, 178-179
 - increased, causing hypomagnesemia, *Apr.*, 194-196
- renal, *Apr.*, 186
- in food, *Apr.*, 176-177
- free, *Apr.*, 187-188
 - ion-selective electrode for, *Apr.*, 187
- metallochrome dyes detecting, *Apr.*, 187
- nuclear magnetic resonance spectroscopy detecting, *Apr.*, 188
- ultrafiltration/equilibrium dialysis determining, *Apr.*, 188
- function of, *Apr.*, 175-176
- homeostasis, *Apr.*, 179-180
- intake reduction causing hypomagnesemia, *Apr.*, 193
- isotope studies, *Apr.*, 186
- metabolism, *Apr.*, 171-218
- mononuclear blood cell, *Apr.*, 181-183
- in muscle, *Apr.*, 183-184
- nutrition and, *Apr.*, 176-178
- physiologic assessment of, *Apr.*, 185-187
- in red blood cells, *Apr.*, 174
 - assessment of, *Apr.*, 184
- redistribution causing hypomagnesemia, *Apr.*, 194
- retention after acute administration, *Apr.*, 186-187
- in serum, *Apr.*, 173-174
 - assessment of, *Apr.*, 184-185
- state of, *Apr.*, 172
- status, assessment of, *Apr.*, 180-188
- in tissue
 - assessment of, *Apr.*, 181-185
 - hard, *Apr.*, 175
 - soft, *Apr.*, 174-175
- transport of, *Apr.*, 175-176
- in water, *Apr.*, 177-178

- Magnetic resonance imaging
 of lung cancer, non-small cell, *Feb.*, 77
 of parathyroid adenomas, *Dec.*, 769-770
 spectroscopy estimating free magnesium, *Apr.*, 188
- Malignancy
 (See also Cancer)
 hypercalcemia of (see Hypercalcemia, of malignancy)
- Malnutrition
 in elderly, causes of, *July*, 448
 in ICU patients, *May*, 277, 278
- Manometry
 in achalasia, *June*, 341-342
 criteria for esophagus motility disorders, primary, *June*, 339
 determination of gastroesophageal reflux, *June*, 367
 tracings in primary esophageal motility disorders, *June*, 336-338
- Meal-induced hypotension: in elderly, *July*, 424
- Mediastinoscopy: in non-small cell lung cancer, *Feb.*, 77-78
- Medications (see Drugs)
- Medroxyprogesterone: in postmenopausal elderly, *July*, 437
- Menopause in elderly
 clinical features of, *July*, 437
 therapy, *July*, 437-439
- Metabolic
 acidosis in ICU, *May*, 276
 alkalosis in ICU, *May*, 273-276
 manifestations
 of hypermagnesemia, *Apr.*, 206
 of hypomagnesemia, *Apr.*, 191-192
- Metallochrome dyes: detecting free magnesium, *Apr.*, 187
- Metapyrone test: in Cushing's syndrome, *Oct.*, 622-623
- Metastases
 Addison's disease due to, *Oct.*, 630
 occult extrathoracic, from lung cancer, CT detecting, *Feb.*, 78-79
- Methylprednisolone: in COPD, *Sept.*, 575
- Metoclopramide: in gastroesophageal reflux, *June*, 371
- Metolazone: in congestive heart failure, *Aug.*, 512
- Metoprolol
 in atrial tachycardia, multifocal, in ICU, *May*, 255-256
 in heart failure, congestive, *Aug.*, 518
- Metyrapone: in Cushing's syndrome, *Oct.*, 627
- Milk-alkali syndrome, *Dec.*, 780
- Milrinone: in congestive heart failure, *Aug.*, 517
- Mineralocorticoids: in hyporeninemic hypoaldosteronism, *Oct.*, 657
- Mithramycin: in hypercalcemia, *Dec.*, 788
- Monitoring
 hemodynamic (see Intensive care unit patients, hemodynamic monitoring complications in)
 pH, 24-hour, in gastroesophageal reflux, *June*, 370
- Mononuclear blood cells: magnesium in, *Apr.*, 181-183
- Mortality
 in heart failure, congestive, effects of vasodilators on, *Aug.*, 522-523
 of lung cancer, non-small cell after surgery, *Feb.*, 84
 after treatment failure, *Feb.*, 80
 in post-myocardial infarction patients, and exercise testing, *Nov.*, 695
- Moxalactam: in COPD, *Sept.*, 574
- Muscle
 cardiac, diagram of, *Aug.*, 479
 dysfunction, striated, esophagus motility disorders in, *June*, 361-366

Muscle (*cont.*)

- dystrophy, idiopathic diffuse esophageal, *June*, 366-367
- fatigue, inspiratory, in COPD, *Sept.*, 587-589
- magnesium in, *Apr.*, 183-184
- Musculoskeletal symptoms: in Addison's disease, *Oct.*, 633
- Myasthenia gravis: esophagus in, *June*, 363-364
- Myocardial infarction
 - exercise testing after, prognostic value of, *Nov.*, 694-699
 - examples of, *Nov.*, 696-699
 - hypomagnesemia and, *Apr.*, 202-203
- Myopathy: of Cushing's syndrome, *Oct.*, 616
- Myotomy
 - in achalasia, *June*, 345-347
 - cricopharyngeal, in oropharyngeal dysphagia, *June*, 365-366
 - in esophageal spasm, diffuse, *June*, 351
 - in nutcracker esophagus, *June*, 354
- Myotonic dystrophy: esophagus in, *June*, 363

Nasopharynx, *June*, 308

Natriuretic factor: atrial, in elderly, *July*, 441

Neck veins: congestive heart failure, *Aug.*, 496

Neonatal (*see* Newborn)

Nephrocalcinosis: in primary hyperparathyroidism, *Dec.*, 757-759

Nephrolithiasis

- in hyperparathyroidism, primary, *Dec.*, 757-759
- hypomagnesemia and, *Apr.*, 204-205

Nephropathy: diabetic, in elderly, *July*, 443

Nephrotoxicity of aminoglycosides

- in ICU, *May*, 268
- prevention of, *May*, 270

Nerve disease: peripheral, esophagus in, *June*, 364-365

Nervous system

- central
 - complications in diabetes, in elderly, *July*, 444
 - manifestations of hypermagnesemia, *Apr.*, 205-206
 - manifestations of hypomagnesemia, *Apr.*, 190
 - sympathetic, in elderly, *July*, 423-424

Neurohumoral compensations: in congestive heart failure, *Aug.*, 492

Neurologic manifestations: of hypercalcemia, *Dec.*, 785

Neuromuscular

- disease of primary hyperparathyroidism, *Dec.*, 759
- manifestations
 - of hypermagnesemia, *Apr.*, 205
 - of hypomagnesemia, *Apr.*, 190

Neuropathic cachexia: diabetic, in elderly, *July*, 444

Neuropathy: diabetic, in elderly, *July*, 444

Neuropeptide Y: Alzheimer's disease, *July*, 447

Neuropharmacotherapeutic agents: in Cushing's syndrome, *Oct.*, 626

Newborn

carrier state for hepatitis B, *Mar.*, 125

hyperparathyroidism in, primary, *Dec.*, 760-761

manifestations of 21-hydroxylase deficiency, *Oct.*, 661

Nifedipine

in achalasia, *June*, 347

in cor pulmonale, chronic hypoxic, *Sept.*, 579

in esophageal spasm, diffuse, *June*, 351

in nutcracker esophagus, *June*, 353

Nitrates

in esophageal spasm, diffuse, *June*, 350

in heart failure, congestive, *Aug.*, 519-520

Nitrofurantoin-induced chronic hepatitis, *Mar.*, 150

Nocturnal
cough in congestive heart failure, *Aug.*, 494

dyspnea, paroxysmal, in congestive heart failure, *Aug.*, 494

Norepinephrine
in elderly, *July*, 423

plasma, as guide to prognosis in congestive heart failure, *Aug.*, 483

Norethindrone: in hyperparathyroidism, in elderly, *July*, 427

Nosocomial infection in ICU, *May*, 264-265

risk, etiology, and therapy in, *May*, 266

Nuclear
angiography in congestive heart failure, *Aug.*, 500

magnetic resonance (*see* Magnetic resonance)

Nutcracker esophagus (*see* Esophagus, nutcracker)

Nutrition
in COPD, *Sept.*, 577-578

magnesium and, *Apr.*, 176-178

malnutrition (*see* Malnutrition)

parenteral, and hypercalcemia, *Dec.*, 781-782

Nutritional
management complications in ICU, *May*, 276-281

support complications in ICU patients, *May*, 277-281

Nystagmus: and hypomagnesemia, *Apr.*, 190

O

Obesity control: in congestive heart failure, *Aug.*, 508

Oculopharyngeal dystrophy: esophagus in, *June*, 363

Office practice (*see* Computer office system)

O,p'DDD: in Cushing's syndrome, *Oct.*, 627

Oropharynx, *June*, 308

dysphagia (*see* Dysphagia, oropharyngeal)

Orthopnea: in congestive heart failure, *Aug.*, 494

Osborn Erecacid: in elderly, *July*, 435

Osmotic agents: causing hypomagnesemia, *Apr.*, 195

Osteitis fibrosa cystica: in primary hyperparathyroidism, *Dec.*, 756

Osteopenia
after corticosteroid therapy in autoimmune chronic active hepatitis, *Mar.*, 147-148

in elderly, *July*, 427-431

clinical syndromes of, *July*, 429-430

therapy of, *July*, 430-431

Osteoporosis: involutional, type I and II, pathophysiology of, *July*, 429

Overlap syndrome, *Sept.*, 586-587

Oxygen therapy in COPD exacerbations, acute, *Sept.*, 575-576

long-term domiciliary, *Sept.*, 580-583

Oxyphenistatin: causing chronic hepatitis, *Mar.*, 150

P

Pain: chest, assessment methodologies, *June*, 323-332

Palsy
bulbar, chronic progressive, esophagus in, *June*, 364

pseudobulbar, esophagus in, *June*, 364

Papaverine: in impotence, in elderly, *July*, 435

Parathyroid
adenomatosis, cystic, *Dec.*, 760

carcinoma in primary hyperparathyroidism, *Dec.*, 760

dysfunction, in elderly, *July*, 424-427

Parathyroid (*cont.*)

- hormone
 - physiology, age-related alteration in, *July*, 424-425
 - radioimmunoassay in primary hyperparathyroidism, *Dec.*, 762-764
 - regulating serum calcium, *Dec.*, 750-751
 - serum concentrations before and after parathyroidectomy, *Dec.*, 768
 - tissue localization by scintigraphy and ultrasound, *Dec.*, 769
- Parkinson's disease: esophageal motility disorders in, *June*, 364
- PEEP: in ICU, weaning off, *May*, 245
- Penile prosthesis: in elderly, *July*, 435
- Peptide: hypercalcemia-associated peptide of malignancy, *Dec.*, 773-775
- Peripheral nerve disease: esophageal motility disorders in, *June*, 364-365
- Peristalsis
 - control mechanisms, scheme of, *June*, 324
 - primary, *June*, 319
 - control of, *June*, 320-323
 - secondary, *June*, 319
- Peritoneal dialysis (*see* Dialysis, peritoneal)
- Personnel training: for computer office system, *Jan.*, 47
- Petrosal sinus: inferior, selective venous sampling, in Cushing's syndrome, *Oct.*, 624-625
- pH monitoring: 24-hour, in gastroesophageal reflux, *June*, 370
- Pharmacologic measures (*see* Drugs)
- Pharynx
 - innervation of, extrinsic, *June*, 309
 - weakness
 - of aged, *June*, 365
 - transient, *June*, 365
- Phentolamine-papaverine: in impotence, in elderly, *July*, 435

- Phenytoin: interactions with other drugs in ICU, *May*, 283
- Pheochromocytoma
 - in elderly, *July*, 424
 - hypercalcemia due to, *Dec.*, 776
 - hypermagnesemia and, *Apr.*, 207
- Phosphate
 - in hypercalcemia, *Dec.*, 790
 - serum, mean, before and after parathyroidectomy, *Dec.*, 768
 - therapy in primary hyperparathyroidism, *Dec.*, 770-771
- Phosphodiesterase inhibitors: in congestive heart failure, *Aug.*, 517
- Physical examination
 - in COPD, *Sept.*, 556-557
 - in heart failure, congestive, *Aug.*, 495-497
 - stress causing hypomagnesemia, *Apr.*, 197-198
- Pigmentary changes: in Addison's disease, *Oct.*, 633
- Pink puffers, *Sept.*, 560, 562
- Pirbuterol
 - in cor pulmonale, chronic hypoxic, *Sept.*, 579
 - in heart failure, congestive, *Aug.*, 518
- Pituitary
 - ACTH-dependent hypercortisolism (*see* Hypercortisolism, pituitary ACTH-dependent)
 - anterior, in elderly, *July*, 409-412
 - function testing, dynamic, in elderly, *July*, 410-411
 - hypothalamic-adrenal axis alterations, in elderly, *July*, 420
 - hypothalamic-testicular axis, in elderly, *July*, 431-432
 - surgery, transsphenoidal, in Cushing's syndrome, *Oct.*, 625
- Pleural effusions: in congestive heart failure, *Aug.*, 497
- Plicamycin: in hypercalcemia, *Dec.*, 788
- Pneumococcal vaccine: in COPD, *Sept.*, 577

- Poliomyelitis: bulbar, esophagus in, *June*, 364
- Polyglandular failure: in elderly, *July*, 446-447
- Polymyositis: esophageal motility disorders in, *June*, 362-363
- Polyneuropathy: familial amyloid, esophageal motility disorders in, *June*, 366
- Postextubation care: ICU, *May*, 247, 250
- Postmenopausal hormonal changes: in elderly, *July*, 436
- Postpubertal manifestations: of 21-hydroxylase deficiency, *Oct.*, 661
- Posture
renin activity response to, plasma, in hyperaldosteronism, *Oct.*, 644
standing, between 8 AM and noon, aldosterone response to, in primary hyperaldosteronism, *Oct.*, 646-647
- Prazosin
in cor pulmonale, chronic hypoxic, *Sept.*, 579
in heart failure, congestive, *Aug.*, 520
- Precocious puberty: in Addison's disease, *Oct.*, 634
- Prednisone withdrawal: in hepatitis B, *Mar.*, 136-138
- Pregnancy: primary hyperparathyroidism during, *Dec.*, 760
- Premenstrual syndrome: and hypomagnesemia, *Apr.*, 205
- Prenalterol: in congestive heart failure, *Aug.*, 518
- Prenatal diagnosis: of 21-hydroxylase deficiency, *Oct.*, 663
- Prepubertal manifestations: of 21-hydroxylase deficiency, *Oct.*, 661
- "Presbyesophagus," *June*, 360-361
- Procainamide in ICU
for atrial fibrillation, *May*, 251
for atrial flutter, *May*, 253
for tachyarrhythmias, *May*, 249
for tachycardia
atrioventricular nodal reentrant, *May*, 255
ventricular, *May*, 258
- Progestin: in elderly female, *July*, 439
- Prolactin: in elderly, *July*, 411
- Propranolol in ICU
for atrial fibrillation, *May*, 251
for atrial flutter, *May*, 252
for tachyarrhythmias, *May*, 249
- Prostaglandin inhibitors: in hypercalcemia, *Dec.*, 790-791
- Prosthesis: penile, in elderly, *July*, 435
- Pseudobulbar palsy: esophagus in, *June*, 364
- Pseudogout: and primary hyperparathyroidism, *Dec.*, 759
- Psychiatric
complications in ICU, *May*, 282-286
disturbances in Cushing's syndrome, *Oct.*, 617
symptoms in Addison's disease, *Oct.*, 633
syndromes (see Intensive care unit patients, psychiatric syndromes in)
- Psychological stress: causing hypomagnesemia, *Apr.*, 197-198
- Psychosis: and hypomagnesemia, *Apr.*, 190
- Puberty: precocious, in Addison's disease, *Oct.*, 634
- Pulmonary
(See also Lung)
artery
perforation due to Swan-Ganz catheter in ICU, *May*, 262-263
wedge pressure as reflection of left ventricular end-diastolic pressure in ICU, *May*, 259-260
barotrauma in ICU, *May*, 240
complications in ICU, *May*, 233-250
hypertension (see Hypertension, pulmonary)

Pulmonary (*cont.*)

- infarction due to Swan-Ganz catheter in ICU, *May*, 263
- thromboemboli in ICU, *May*, 239-240
- vasodilators in chronic hypoxic cor pulmonale, *Sept.*, 578-580
- Pulse rate: in congestive heart failure, *Aug.*, 496
- Pyogenic abscesses: after interferon in hepatitis B, *Mar.*, 134

Q

- Quality of life: with combination chemotherapy for non-small cell lung cancer, *Feb.*, 95
- Quinacrine: in hepatitis B, *Mar.*, 138
- Quinidine in ICU
 - for atrial fibrillation, *May*, 251
 - for atrial flutter, *May*, 253
 - interactions with other drugs, *May*, 283
 - for tachyarrhythmias, *May*, 248
 - for tachycardia, atrioventricular nodal reentrant, *May*, 255
- Q waves: examples of elevation over, *Nov.*, 691-693

R

- Radiation
 - diagnostic (*see* Radiography)
 - therapeutic (*see* Radiotherapy)
- Radiocontrast materials causing renal complications in ICU, *May*, 268
- prevention of, *May*, 270
- Radiography
 - of bone disease in primary hyperparathyroidism, *Dec.*, 757
 - chest
 - in achalasia, *June*, 341
 - in emphysema, *Sept.*, 560
 - in heart failure, congestive, *Aug.*, 498-499
 - in lung cancer, *Feb.*, 70
 - in lung disease, chronic obstructive, *Sept.*, 559-560
 - in respiratory failure complications in ICU, *May*, 242
 - in respiratory failure in ICU, *May*, 236, 237, 238
- Radioimmunoassay of parathyroid hormone
 - in hypercalcemia of malignancy, *Dec.*, 771-772
 - in hyperparathyroidism, primary, *Dec.*, 762-764
- Radiology: in emphysema diagnosis, *Sept.*, 559-560
- Radionuclide studies
 - in achalasia, *June*, 341
 - in gastroesophageal reflux, *June*, 370
 - in lung cancer, non-small cell, *Feb.*, 78
- Radiotherapy
 - conventional, in Cushing's syndrome, *Oct.*, 625-626
 - of lung cancer, non-small cell, *Feb.*, 85-89
 - as adjuvant for 'positive margins', *Feb.*, 87
 - curative, *Feb.*, 85-86
 - postoperative, *Feb.*, 86-87
 - preoperative, *Feb.*, 86
 - prophylactic cranial, *Feb.*, 87
 - as surgical adjuvant, *Feb.*, 86-87
 - for unresectable tumors, *Feb.*, 88-89
- Rales: in congestive heart failure, *Aug.*, 496-497
- Ranitidine
 - in gastroesophageal reflux, *June*, 371
 - in sclerosis, progressive systemic, *June*, 358
- Records: computerized medical record system, *Jan.*, 41-43
- Red blood cells, magnesium in, *Apr.*, 174
- assessment of, *Apr.*, 184
- Reflux (*see* Gastroesophageal reflux)
- Renin
 - angiotensin-aldosterone system, *Oct.*, 641
 - in elderly, *July*, 421-422

- in heart failure, congestive, *Aug.*, 489
- plasma renin activity response to posture and diuretic, in hyperaldosteronism, *Oct.*, 644
- Reproductive
 - hormonal changes in elderly male, *July*, 431
 - physiology in elderly male, *July*, 431-436
 - system, female, in elderly, *July*, 436-439
- Reserpine: in Cushing's syndrome, *Oct.*, 626
- Respiration: Cheyne-Stokes, in congestive heart failure, *Aug.*, 494
- Respiratory failure
 - acute (see Intensive care unit patients, respiratory failure in, acute)
 - as complication of total parenteral nutrition in ICU, *May*, 281
 - function studies in COPD, *Sept.*, 557-559
 - infections in COPD, prophylaxis of, *Sept.*, 576-577
- Rheumatoid arthritis: esophagus in, *June*, 359
- Ribavirin: in hepatitis B, *Mar.*, 138
- Rifampin: causing adrenal insufficiency, *Oct.*, 632
- Roentgenography (see Radiography)
- RU 486: in Cushing's syndrome, *Oct.*, 627
- Rumination syndrome, *June*, 366

S

- Saline infusion test: in hyperaldosteronism, *Oct.*, 644
- Sarcomere length: and left ventricular pressure (in dog), *Aug.*, 486
- Scintigraphy: for localization of parathyroid tissue, *Dec.*, 769
- Sclerosis
 - multiple, esophageal motility disorders in, *June*, 364
 - systemic, progressive, esophageal motility disorders in, *June*, 355-358
 - clinical features of, *June*, 356-357
 - diagnosis of, *June*, 357
 - pathophysiology, *June*, 355-356
 - treatment, *June*, 358
- Sclerotherapy: esophageal, *June*, 367
- Seizures: and hypomagnesemia, *Apr.*, 190
- Septic shock causing renal complications in ICU, *May*, 267
- prevention of, *May*, 269
- Sexual function: in elderly male, *July*, 433-435
- Shock
 - hemorrhagic, causing renal complications in ICU, *May*, 267
 - prevention of, *May*, 270
 - septic, causing renal complications in ICU, *May*, 267
 - prevention of, *May*, 269
- Sinus: inferior petrosal, selective venous sampling, in Cushing's syndrome, *Oct.*, 624-625
- Sinusoid: hepatic, in chronic active liver disease, *Mar.*, 118
- Sjögren's syndrome: primary, esophagus in, *June*, 359
- Sleep-disordered breathing: in COPD, *Sept.*, 583-587
- Smoking
 - cessation in COPD, *Sept.*, 566-568
 - passive, and lung cancer, *Feb.*, 62-64
 - self-help quit smoking materials, *Feb.*, 63
- Soft tissue: magnesium in, *Apr.*, 174-175
- Software, computer, *Jan.*, 10-11
- maintenance, *Jan.*, 48-49
- Somatostatin C: in elderly, *July*, 409-410
- Spasm (see Esophagus, spasm, diffuse)

Spectroscopy: nuclear magnetic resonance, estimating free magnesium, *Apr.*, 188

Spironolactone
in heart failure, congestive, *Aug.*, 510-511
dosage and pharmacokinetic characteristics of, *Aug.*, 512
in hyperaldosteronism, primary, *Oct.*, 649-651

Sputum cytology: detecting lung cancer, *Feb.*, 70

Starvation: in ICU patients, *May*, 277, 278

Steroidogenesis: adrenal, *Oct.*, 658

Stones (*see* Nephrolithiasis)

Streptococcus pneumoniae: prophylaxis, in COPD, *Sept.*, 577

Stress: causing hypomagnesemia, *Apr.*, 197-198

Striated muscle dysfunction: esophageal motility disorders in, *June*, 361-366

Sucralfate: in gastroesophageal reflux, *June*, 371

Sulfonamides: causing chronic hepatitis, *Mar.*, 150

Supraclavicular biopsy: in non-small cell lung cancer, *Feb.*, 78

Supraventricular tachycardia, paroxysmal, in ICU patients, *May*, 253-255
definition of, *May*, 253

Swan-Ganz catheter (*see* Intensive care unit patients, hemodynamic monitoring complications in)

Sympathetic nervous system: in elderly, *July*, 423-424

T

Tachyarrhythmias: emergency drugs for, in ICU, *May*, 248-249

Tachycardia
in ICU (*see* Intensive care unit patients, tachycardia in)
ventricular, exercise test-induced, *Nov.*, 720-722

Tachypnea: in congestive heart failure, *Aug.*, 496

Telephone response support centers: for computer office system, *Jan.*, 49

Tension: sustained, in ICU patients, therapy of, *May*, 285

Testicular-pituitary-hypothalamic axis: in elderly, *July*, 431-432

Tetany: and hypomagnesemia, *Apr.*, 190

Theophylline
in COPD, *Sept.*, 568-569
 β_2 -agonists and ipratropium with, *Sept.*, 571
for inspiratory muscle fatigue, *Sept.*, 588-589

Thiazides
in heart failure, congestive, *Aug.*, 510
hypercalcemia due to, *Dec.*, 779

Thromboemboli: pulmonary, in ICU, *May*, 239-240

Thromboembolic pulmonary hypertension: chronic, differential diagnosis, *Sept.*, 565

Thrombosis: due to Swan-Ganz catheter in ICU, *May*, 263

Thyroid
anatomy, in elderly, *July*, 412
cancer, in elderly, *July*, 418
disease, in elderly, *July*, 412-418
function tests, in elderly, *July*, 412-414
in hyperthyroidism, *July*, 417
physiology alterations, in elderly, *July*, 413
-stimulating hormone in Alzheimer's disease, *July*, 447

Thyrotoxicosis: causing hypercalcemia, *Dec.*, 776

Thyrotropin: in elderly, *July*, 411

Tissue
connective tissue disease, mixed, esophagus in, *June*, 358
magnesium in (*see* Magnesium, in tissue)

Tobacco
(*See also* Smoking)
lung cancer and, *Feb.*, 61-62

Tomography
computed

- in Addison's disease, *Oct.*, 637
- in Cushing's syndrome, *Oct.*, 624
- in emphysema, *Sept.*, 561
- in hyperaldosteronism, primary, *Oct.*, 648
- in lung cancer, non-small cell, *Feb.*, 77
- in lung disease, chronic obstructive, *Sept.*, 560
- for metastases, occult extra-thoracic, from lung cancer, *Feb.*, 78-79
- for preoperative localization of parathyroid adenomas, *Dec.*, 767-769
- standard, in non-small cell lung cancer, *Feb.*, 77

Toxicity

- of azathioprine in autoimmune chronic active hepatitis, *Mar.*, 147-148
- of corticosteroids in autoimmune chronic active hepatitis, *Mar.*, 147-148
- of interferon in hepatitis B, *Mar.*, 134
- nephrotoxicity of aminoglycosides in ICU, *May*, 268
- prevention of, *May*, 270
- vitamin A, causing hypercalcemia, *Dec.*, 780
- vitamin D, causing hypercalcemia, *Dec.*, 777-778

Transfer factor: in hepatitis B, *Mar.*, 126, 138

Transforming-growth factor: in humoral hypercalcemia of malignancy, *Dec.*, 775

Transfusion: perioperative, in non-small cell lung cancer, *Feb.*, 81

Transplantation

- heart, in congestive heart failure, *Aug.*, 525-527
- kidney, hypercalcemia after, *Dec.*, 782

liver, in chronic hepatitis, *Mar.*, 151

Trazadone: in nutcracker esophagus, *June*, 354

Triamterene: in congestive heart failure, *Aug.*, 512

Tricyclic antidepressants: in psychiatric ICU syndromes, *May*, 286

Tuberculous Addison's disease, *Oct.*, 629

Tumor

- adrenal (*see* Cushing's syndrome, adrenal tumors causing)
- markers in staging of lung cancer, *Feb.*, 79

U

Ultrafiltration/equilibrium dialysis: determining free magnesium, *Apr.*, 188

Ultrasound: for localization of parathyroid tissue, *Dec.*, 769

Urapidil: in chronic hypoxic cor pulmonale, *Sept.*, 579

V

Vaccine

- influenza, in COPD, *Sept.*, 576-577
- pneumococcal, in COPD, *Sept.*, 577

Vagal

- inhibitor pathway to LES, schematic of, *June*, 325
- maneuvers in atrioventricular nodal reentrant tachycardia in ICU, *May*, 255

Vasodilators

- in heart failure, congestive, *Aug.*, 519-525
- clinical experience, *Aug.*, 519-521
- effects on mortality, *Aug.*, 522-523
- new directions, *Aug.*, 524
- rationale for use, *Aug.*, 519
- pulmonary, in chronic hypoxic cor pulmonale, *Sept.*, 578-580

Vein(s)

- catheterization, selective, of parathyroid adenomas, *Dec.*, 770
- effluent study, bilateral, in primary hyperaldosteronism, *Oct.*, 648-649
- neck, in congestive heart failure, *Aug.*, 496
- sampling, selective, of inferior petrosal sinus, in Cushing's syndrome, *Oct.*, 624-625

Ventilation

- intermittent mandatory, for weaning in ICU, *May*, 244-245
- mechanical, in ICU (*see* Intensive care unit patients, mechanical ventilation in)
- pressure support, for weaning in ICU, *May*, 245

Ventilator settings (*see* Intensive care unit patients, ventilator settings in)

Ventricle

- arrhythmias (*see* Arrhythmias, ventricular)
- cardiac contraction mechanics in, *Aug.*, 485-488
- contractions, premature, exercise test-induced, *Nov.*, 720-722
- ectopy during passage of Swan-Ganz catheter in ICU, *May*, 262

left

- failure due to cardiomyopathy, survival curves in, *Aug.*, 478
- pressure, end-diastolic, pulmonary artery wedge pressure as reflection of, in ICU, *May*, 259-260
- pressure, and sarcomere length (in dog), *Aug.*, 486
- pressure-volume relationships, *Aug.*, 487
- tachycardia
 - exercise test-induced, *Nov.*, 720-722
 - in ICU (*see* Intensive care unit patients, tachycardia in, ventricular)

Verapamil in ICU

- for atrial fibrillation, *May*, 251
- for atrial flutter, *May*, 252
- for tachyarrhythmias, *May*, 248
- for tachycardia
 - atrial, multifocal, *May*, 256
 - atrioventricular nodal reentrant, *May*, 255

Vessels

- cardiovascular manifestations of hypercalcemia, *Dec.*, 785
- cerebrovascular accident, esophageal motility disorders in, *June*, 364
- collagen vascular diseases, esophagus in, *June*, 358-359

VIP-omas: causing hypercalcemia, *Dec.*, 777

Vitamin

- A toxicity causing hypercalcemia, *Dec.*, 780
- D toxicity causing hypercalcemia, *Dec.*, 777-778

W

Water

- magnesium in, *Apr.*, 177-178
- metabolism, in elderly, *July*, 439-441

Waterhouse-Friderichsen syndrome: Addison's disease after, *Oct.*, 631

Waves: Q, examples of elevation over, *Nov.*, 691-693

Word processing requirements: of medical office, *Jan.*, 43

WR2721: in hypercalcemia, *Dec.*, 791

X

Xamoterol: in congestive heart failure, *Aug.*, 518

Z

Zenker's diverticulum, *June*, 362

-

-

,

,

re:

,

91

988